We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Leica Biosystems Launches HistoCore PEGASUS Plus Dual-Retort Tissue Processor in Europe

By LabMedica International staff writers
Posted on 04 May 2022

Leica Biosystems (Nussloch, Germany) has launched a compact, dual-retort tissue processor, the HistoCore PEGASUS Plus. More...

For the first time, the technology will now be available to medium-sized laboratories, enabling them to optimize histopathology workflows.

Mid-sized laboratories will now be able to run multiple protocols in parallel on a single instrument, providing a solution that adapts to their workflow needs, and reduces unnecessary hands-on time. The dual retorts on HistoCore PEGASUS Plus increase capacity by 33% compared to a typical 300-cassette single-retort tissue processor. The HistoCore PEGASUS Plus builds on more than 15 years of experience with the larger HistoCore PELORIS system, and also incorporates Leica’s pioneering integrated track and trace technology, the HistoCore I-Scan. This enables laboratories to capture and store individual cassette information, user interactions, and reagent levels, delivering high confidence in the quality of results.

Labs face problems with tissue processing, creating the need for a solution to under- or over-processing. This occurs when labs have to process both biopsy and large routine tissue specimens in the same processing run. In an ideal scenario, biopsy and larger sample tissues would be processed separately using a protocol specific to the specimen. The HistoCore PEGASUS Plus tissue processor addresses this issue by bringing a scalable workflow solution to all labs of all sizes, ensuring optimal conditions for each tissue type without slowing down the lab. The HistoCore PEGASUS Plus is now available in Europe and where the CE mark is accepted for country-specific registration.

“We understand that labs are under pressure of staff shortages, increased daily throughput, and additional complexities with processing different types and sizes of tissue,” said Christine Munz, Vice President of Core Histology at Leica Biosystems. “Large, high throughput labs have confidence in the power and robust performance of our HistoCore PELORIS tissue processing technology. The new PEGASUS PLUS now brings these benefits to mid-sized labs.”

Related Links:
Leica Biosystems 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.